<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03970434</url>
  </required_header>
  <id_info>
    <org_study_id>CUH_2019_MSM</org_study_id>
    <nct_id>NCT03970434</nct_id>
  </id_info>
  <brief_title>Drug Concentration of Metformin According to Sampling Method</brief_title>
  <official_title>Clinical Trial to Evaluate Drug Concentration of Metformin According to Sampling Method in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chonbuk National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assess the drug concentration of metformin in healthy adult volunteers according
      to the sampling method.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2019</start_date>
  <completion_date type="Actual">June 5, 2019</completion_date>
  <primary_completion_date type="Actual">June 5, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Metformin</measure>
    <time_frame>10 hours</time_frame>
    <description>Compare the concentration of Metformin measured from Venous blood collection and Peripheral blood collection.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Venous blood collection</intervention_name>
    <description>Venous blood collection</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Peripheral blood collection</intervention_name>
    <description>Peripheral blood collection</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects who, at the time of screening, are the age of older than 19
             years

          -  Subjects who have BMI more than 17.5kg/m2 and less than 30.5kg/m2 and body weight more
             than 55kg

          -  There is no congenital disease or within 3 years of chronic diseases

          -  Healthy is defined as no clinically relevant abnormalities identified by a detailed
             medical history, full physical examination, including blood pressure and pulse rate
             measurement, ECG or clinical laboratory tests

          -  Subjects who signed and dated the informed consent form(approved by IRB) after
             understanding fully to hear a detailed explanation in the clinical trial

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease

          -  A subject with any history of gastrointestinal disease (e.g., Crohn's disease, acute
             or chronic pancreatitis, and others) and surgery (except for simple appendectomy or
             repair of a hernia), which can influence the absorption of investigational products

          -  A subject who has the following clinical laboratory test results Liver Function Test
             (AST, ALT) &gt; two times the upper limit of the normal range

          -  History of regular alcohol consumption exceeding 210g/week(12g = 125 mL of wine, 10g =
             250 mL of beer, 10g = 50 mL of hard liquor) within 6 months of Screening

          -  A subject who has participated in any other clinical trials and had medication within
             3 months prior to the first administration of investigational product.

          -  A subject with a history of drug abuse or a positive urine drug screening for drug
             abuse within 1 year

          -  A subject who has taken the drugs that induce and suppress drug- metabolizing enzymes
             within 30 days prior to investigational product administration

          -  A smoker who consumes more than 20 cigarettes/day within 6 months

          -  A subject who has taken any ethical-the-counter drug or has taken any over-
             the-counter drug within 10 days before the investigational product administration

          -  A subject who has donated whole blood within 2 months or blood components within 1
             month prior to the investigational product administration

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 17, 2019</study_first_submitted>
  <study_first_submitted_qc>May 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>June 12, 2019</last_update_submitted>
  <last_update_submitted_qc>June 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonbuk National University Hospital</investigator_affiliation>
    <investigator_full_name>Min-Gul Kim, MD, PhD</investigator_full_name>
    <investigator_title>Center for Clinical Pharmacology</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

